{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:46:57Z","timestamp":1794955617783,"version":"4.9.1"},"reference-count":186,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cardiovascular disease (CVD) constitutes the most common cause of death worldwide. In Europe alone, approximately 4 million people die annually due to CVD. The leading component of CVD leading to mortality is myocardial infarction (MI). MI is classified into several types. Type 1 is associated with atherosclerosis, type 2 results from inadequate oxygen supply to cardiomyocytes, type 3 is defined as sudden cardiac death, while types 4 and 5 are associated with procedures such as percutaneous coronary intervention and coronary artery bypass grafting, respectively. Of particular note is type 1, which is also the most frequently occurring form of MI. Factors predisposing to its occurrence include, among others, high levels of low-density lipoprotein cholesterol (LDL-C) in the blood, cigarette smoking, chronic kidney disease (CKD), diabetes mellitus (DM), hypertension, and familial hypercholesterolaemia (FH). The primary objective of this review is to elucidate the issues with regard to type 1 MI. Our paper delves into, amidst other aspects, its pathogenesis, risk assessment, diagnosis, pharmacotherapy, and interventional treatment options in both acute and long-term conditions.<\/jats:p>","DOI":"10.3390\/ijms25137295","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T12:58:42Z","timestamp":1719925122000},"page":"7295","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["From Atherosclerotic Plaque to Myocardial Infarction\u2014The Leading Cause of Coronary Artery Occlusion"],"prefix":"10.3390","volume":"25","author":[{"given":"Ewelina","family":"M\u0142ynarska","sequence":"first","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5502-0335","authenticated-orcid":false,"given":"Witold","family":"Czarnik","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7469-7056","authenticated-orcid":false,"given":"Piotr","family":"Fularski","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6892-6199","authenticated-orcid":false,"given":"Joanna","family":"Hajdys","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0447-8510","authenticated-orcid":false,"given":"Gabriela","family":"Majchrowicz","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3490-3480","authenticated-orcid":false,"given":"Magdalena","family":"Stabrawa","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Franczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pcad.2021.12.001","article-title":"The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease","volume":"70","author":"Kaminsky","year":"2022","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: Epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-981-10-4307-9_9","article-title":"Myocardial Infarction and Exercise Training: Evidence from Basic Science","volume":"999","author":"Rodrigues","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth Universal Definition of Myocardial Infarction","volume":"72","author":"Thygesen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1161\/ATVBAHA.119.312578","article-title":"Myocardial Infarction-From Atherosclerosis to Thrombosis","volume":"39","author":"Palasubramaniam","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","article-title":"Atherosclerosis: Recent developments","volume":"185","author":"Lusis","year":"2022","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/CS20180306","article-title":"Atherosclerosis and inflammation: Overview and updates","volume":"132","author":"Geovanini","year":"2018","journal-title":"Clin. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41569-019-0227-9","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"16","author":"Basatemur","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gui, Y., Zheng, H., and Cao, R.Y. (2022). Foam Cells in Atherosclerosis: Novel Insights into Its Origins, Consequences, and Molecular Mechanisms. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.845942"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"(1988). Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch. Intern. Med., 148, 36\u201369.","DOI":"10.1001\/archinte.148.1.36"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"(1993). Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA, 269, 3015\u20133023.","DOI":"10.1001\/jama.269.23.3015"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/01.CIR.101.11.1249","article-title":"Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: Effect of vitamin E supplementation","volume":"101","author":"Iuliano","year":"2000","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"National Heart, Lung, and Blood Institute (2011). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics, 128, S213\u2013S256.","DOI":"10.1542\/peds.2009-2107C"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A Modern Approach to Dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/ATVBAHA.113.300156","article-title":"Smoking and cardiovascular disease: Mechanisms of endothelial dysfunction and early atherogenesis","volume":"34","author":"Messner","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fularski, P., Krzemi\u0144ska, J., Lewandowska, N., M\u0142ynarska, E., Saar, M., Wronka, M., Rysz, J., and Franczyk, B. (2023). Statins in Chronic Kidney Disease-Effects on Atherosclerosis and Cellular Senescence. Cells, 12.","DOI":"10.3390\/cells12131679"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.ackd.2011.03.003","article-title":"Hypertension and CKD","volume":"18","author":"VanDeVoorde","year":"2011","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1467-789X.2001.00042.x","article-title":"The biology of white adipocyte proliferation","volume":"2","author":"Hausman","year":"2001","journal-title":"Obes. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/ATVBAHA.113.302077","article-title":"Essential role of CD11a in CD8+ T-cell accumulation and activation in adipose tissue","volume":"34","author":"Jiang","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Luo, J., He, Z., Li, Q., Lv, M., Cai, Y., Ke, W., Niu, X., and Zhang, Z. (2023). Adipokines in atherosclerosis: Unraveling complex roles. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1235953"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kim, H.L., and Kim, S.H. (2019). Pulse Wave Velocity in Atherosclerosis. Front. Cardiovasc. Med., 6.","DOI":"10.3389\/fcvm.2019.00041"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Verhaar, B.J.H., Prodan, A., Nieuwdorp, M., and Muller, M. (2020). Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients, 12.","DOI":"10.3390\/nu12102982"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.hjr.0000368193.24732.66","article-title":"Hyperglycaemia and the vessel wall: The pathophysiological aspects on the atherosclerotic burden in patients with diabetes","volume":"17","author":"Ceriello","year":"2010","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2047487319878373","article-title":"The link between diabetes and atherosclerosis","volume":"26","author":"Prattichizzo","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1006\/bbrc.1999.0543","article-title":"Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes","volume":"257","author":"Browatzki","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1089\/ars.2012.4641","article-title":"Angiotensin II, NADPH oxidase, and redox signaling in the vasculature","volume":"19","author":"Montezano","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Perrotta, I. (2022). Atherosclerosis: From Molecular Biology to Therapeutic Perspective. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073444"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCRESAHA.115.307611","article-title":"Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease","volume":"118","author":"Herrington","year":"2016","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","article-title":"Pathogenesis of atherosclerosis","volume":"47","author":"Falk","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCRESAHA.111.261388","article-title":"Aging and atherosclerosis: Mechanisms, functional consequences, and potential therapeutics for cellular senescence","volume":"111","author":"Wang","year":"2012","journal-title":"Circ. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"g3617","DOI":"10.1136\/bmj.g3617","article-title":"Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial","volume":"348","author":"Jacobsen","year":"2014","journal-title":"BMJ"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e029420","DOI":"10.1136\/bmjopen-2019-029420","article-title":"Evaluating the effectiveness of the NHS Health Check programme in South England: A quasi-randomised controlled trial","volume":"9","author":"Kennedy","year":"2019","journal-title":"BMJ Open"},{"key":"ref_36","first-page":"CD009009","article-title":"General health checks in adults for reducing morbidity and mortality from disease","volume":"1","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.3399\/bjgp14X676456","article-title":"Effectiveness of general practice-based health checks: A systematic review and meta-analysis","volume":"64","author":"Si","year":"2014","journal-title":"Br. J. Gen. Pr."},{"key":"ref_38","unstructured":"SCORE2 working group and ESC Cardiovascular risk collaboration (2021). SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J., 42, 2439\u20132454."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.jvca.2021.09.033","article-title":"Score2: A New Updated Algorithm to Predict Cardiovascular Disease Risk in Europe","volume":"36","author":"Ramakrishna","year":"2022","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s11606-019-05361-4","article-title":"The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults","volume":"35","author":"Nanna","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"a3083","DOI":"10.1136\/bmj.a3083","article-title":"Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: Population based observational cohort study","volume":"338","author":"Westendorp","year":"2009","journal-title":"BMJ"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1532-5415.2010.02767.x","article-title":"Competing risk of death: An important consideration in studies of older adults","volume":"58","author":"Berry","year":"2010","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"SCORE2-OP working group and ESC Cardiovascular risk collaboration (2021). SCORE2-OP risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J., 42, 2455\u20132467.","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"ref_44","first-page":"e7093","article-title":"A Comparison of Four Cardiovascular Risk Assessment Instruments in Saudi Patients","volume":"12","author":"Hasabullah","year":"2020","journal-title":"Cureus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: The updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e009217","DOI":"10.1161\/JAHA.118.009217","article-title":"Estimated Life Expectancy without Recurrent Cardiovascular Events in Patients with Vascular Disease: The SMART-REACH Model","volume":"7","author":"Kaasenbrood","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/eurjpc\/zwaa128","article-title":"Prediction of recurrent event in patients with coronary heart disease: The EUROASPIRE Risk Model","volume":"29","author":"Ueda","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/EDE.0b013e3181a39056","article-title":"Prognostic models with competing risks: Methods and application to coronary risk prediction","volume":"20","author":"Wolbers","year":"2009","journal-title":"Epidemiology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S2213-8587(16)30057-2","article-title":"Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: A population-level cohort study","volume":"4","author":"Brownrigg","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/1741826710394270","article-title":"Contemporary model for cardiovascular risk prediction in people with type 2 diabetes","volume":"18","author":"Kengne","year":"2011","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/cs1010671","article-title":"The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/1474515119856207","article-title":"Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)","volume":"18","author":"Rossello","year":"2019","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/cphy.c150006","article-title":"Pathophysiology of Myocardial Infarction","volume":"5","author":"Frangogiannis","year":"2015","journal-title":"Compr. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1053\/j.jvca.2019.10.005","article-title":"The Pathophysiology of Myocardial Ischemia and Perioperative Myocardial Infarction","volume":"34","author":"Smit","year":"2020","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1871525714666161216100553","article-title":"Pathophysiology of Myocardial Infarction and Acute Management Strategies","volume":"14","author":"Tibaut","year":"2017","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s12013-015-0553-4","article-title":"Myocardial Infarction: Symptoms and Treatments","volume":"72","author":"Lu","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","article-title":"Update on acute coronary syndromes: The pathologists\u2019 view","volume":"34","author":"Falk","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ehj.2004.01.002","article-title":"Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece","volume":"25","author":"Schaar","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Luo, X., Lv, Y., Bai, X., Qi, J., Weng, X., Liu, S., Bao, X., Jia, H., and Yu, B. (2021). Plaque Erosion: A Distinctive Pathological Mechanism of Acute Coronary Syndrome. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.711453"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e012307","DOI":"10.1161\/JAHA.119.012307","article-title":"Presenting Symptoms in Men and Women Diagnosed with Myocardial Infarction Using Sex-Specific Criteria","volume":"8","author":"Ferry","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_61","unstructured":"Gul, Z., and Makaryus, A.N. (2024). Silent Myocardial Ischemia. 2023 Jan 19. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Theofilis, P., Antonopoulos, A.S., Sagris, M., Papanikolaou, A., Oikonomou, E., Tsioufis, K., and Tousoulis, D. (2024). Silent Myocardial Ischemia: From Pathophysiology to Diagnosis and Treatment. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020259"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0735-1097(85)80213-8","article-title":"Electrocardiographic findings in acute right ventricular infarction: Sensitivity and specificity of electrocardiographic alterations in right precordial leads V4R, V3R, V1, V2, and V3","volume":"6","author":"Alcasena","year":"1985","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0735-1097(01)01307-9","article-title":"Prognostic value of ST segment depression in acute coronary syndromes: Insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb\/IIIa Antagonism for the Reduction of Acute Global Organization Network","volume":"38","author":"Kaul","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/eurheartj\/ehi395","article-title":"Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes","volume":"26","author":"Savonitto","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.amjcard.2011.08.002","article-title":"Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials)","volume":"109","author":"Damman","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/eurheartj\/ehi026","article-title":"Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population","volume":"26","author":"Jacobsen","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ahj.2013.04.010","article-title":"Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes","volume":"166","author":"Tan","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)31923-8","article-title":"High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: A stepped-wedge, cluster-randomised controlled trial","volume":"392","author":"Shah","year":"2018","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jacc.2017.07.718","article-title":"Clinical Use of High-Sensitivity Cardiac Troponin in Patients with Suspected Myocardial Infarction","volume":"70","author":"Twerenbold","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1056\/NEJMoa1803377","article-title":"Application of High-Sensitivity Troponin in Suspected Myocardial Infarction","volume":"380","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/2048872616653229","article-title":"Rapid rule out of acute myocardial infarction: Novel biomarker-based strategies","volume":"6","author":"Mueller","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2048872616653228","article-title":"Editor\u2019s Choice-Rule-in of acute myocardial infarction: Focus on troponin","volume":"6","author":"Giannitsis","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1093\/eurheartj\/ehy514","article-title":"Impact of age on the performance of the ESC 0\/1h-algorithms for early diagnosis of myocardial infarction","volume":"39","author":"Boeddinghaus","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijcard.2016.01.213","article-title":"Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T\u2014Sub-analysis from the TRAPID-AMI study","volume":"209","author":"Lindahl","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e007297","DOI":"10.1161\/JAHA.117.007297","article-title":"Relations of Sex to Diagnosis and Outcomes in Acute Coronary Syndrome","volume":"7","author":"Neumann","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCULATIONAHA.117.028901","article-title":"0\/1-Hour Triage Algorithm for Myocardial Infarction in Patients with Renal Dysfunction","volume":"137","author":"Twerenbold","year":"2018","journal-title":"Circulation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1373\/clinchem.2015.249508","article-title":"Two-Hour Algorithm for Triage toward Rule-Out and Rule-In of Acute Myocardial Infarction by Use of High-Sensitivity Cardiac Troponin I","volume":"62","author":"Boeddinghaus","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ahj.2022.10.007","article-title":"Diagnostic discrimination of a novel high-sensitivity cardiac troponin I assay and derivation\/validation of an assay-specific 0\/1h-algorithm","volume":"255","author":"Koechlin","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/heartjnl-2019-316343","article-title":"Safety and efficacy of the European Society of Cardiology 0\/1-hour algorithm for diagnosis of myocardial infarction: Systematic review and meta-analysis","volume":"106","author":"Chiang","year":"2020","journal-title":"Heart"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2016.01.112","article-title":"Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0h\/1h-algorithm for the early diagnosis of acute myocardial infarction","volume":"207","author":"Nestelberger","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.120.052982","article-title":"Novel Criteria for the Observe-Zone of the ESC 0\/1h-hs-cTnT Algorithm","volume":"144","author":"Nestelberger","year":"2021","journal-title":"Circulation"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jacc.2021.07.055","article-title":"Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction","volume":"78","author":"Lee","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"n355","DOI":"10.1136\/bmj.n355","article-title":"High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: Pragmatic, cluster randomised, crossover trial","volume":"372","author":"Stewart","year":"2021","journal-title":"BMJ"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-139-12-200312160-00007","article-title":"Chest pain relief by nitroglycerin does not predict active coronary artery disease","volume":"139","author":"Henrikson","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e018881","DOI":"10.1161\/JAHA.120.018881","article-title":"Impact of Morphine Treatment with and without Metoclopramide Coadministration on Myocardial and Microvascular Injury in Acute Myocardial Infarction: Insights from the Randomized MonAMI Trial","volume":"10","author":"Stiermaier","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1160\/TH15-12-0944","article-title":"P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study","volume":"116","author":"Silvain","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ajem.2020.11.003","article-title":"Effects of morphine on P2Y12 platelet inhibitors in patients with acute myocardial infarction: A meta-analysis","volume":"41","author":"Zhang","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.113.003653","article-title":"Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial","volume":"128","author":"Ibanez","year":"2013","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.jacc.2016.03.522","article-title":"Early Intravenous Beta-Blockers in Patients with ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention","volume":"67","author":"Roolvink","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/2048872619830609","article-title":"Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials","volume":"9","author":"Hoedemaker","year":"2020","journal-title":"Eur. Heart J. Acute Cardiovasc. Care."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijcard.2016.08.293","article-title":"Intravenous \u03b2-blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials","volume":"223","author":"Elgendy","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2016.02.056","article-title":"Validation of BARC Bleeding Criteria in Patients with Acute Coronary Syndromes: The TRACER Trial","volume":"67","author":"Vranckx","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): The randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"(1994). Collaborative overview of randomised trials of antiplatelet therapy\u2014I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration. BMJ, 308, 81\u2013106. Erratum in: BMJ 1994, 308, 1540.","DOI":"10.1136\/bmj.308.6921.81"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease","volume":"384","author":"Jones","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: The international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1136\/bmj.e553","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: Systematic review and meta-analysis","volume":"344","author":"Silvain","year":"2012","journal-title":"BMJ"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (2006). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med., 354, 1464\u20131476.","DOI":"10.1056\/NEJMoa055443"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/CIRCULATIONAHA.111.018549","article-title":"Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase","volume":"124","author":"Pinto","year":"2011","journal-title":"Circulation"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12928-021-00829-9","article-title":"CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022","volume":"37","author":"Ozaki","year":"2022","journal-title":"Cardiovasc. Interv. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1161\/CIRCULATIONAHA.108.793745","article-title":"Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: Bayesian hierarchical meta-analyses of randomized controlled trials and observational studies","volume":"119","author":"Huynh","year":"2009","journal-title":"Circulation"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e015186","DOI":"10.1161\/JAHA.119.015186","article-title":"Comparison of Reperfusion Strategies for ST-Segment-Elevation Myocardial Infarction: A Multivariate Network Meta-analysis","volume":"9","author":"Fazel","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Fibrinolytic Therapy Trialists\u2019 (FTT) Collaborative Group (1994). Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 343, 311\u2013322. Erratum in: Lancet 1994, 343, 742.","DOI":"10.1016\/S0140-6736(94)91161-4"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa0808276","article-title":"Routine early angioplasty after fibrinolysis for acute myocardial infarction","volume":"360","author":"Cantor","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction","volume":"368","author":"Armstrong","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMoa050849","article-title":"Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction","volume":"353","author":"Gershlick","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cjca.2018.02.005","article-title":"Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)","volume":"34","author":"Arbel","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa066139","article-title":"Coronary intervention for persistent occlusion after myocardial infarction","volume":"355","author":"Hochman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/eurheartj\/ehn486","article-title":"Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: Insights from Occluded Artery Trial","volume":"30","author":"Menon","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_126","first-page":"CD004815","article-title":"Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era","volume":"2016","author":"Fanning","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.amjcard.2016.11.005","article-title":"Meta-Analysis of Randomized Trials of Long-Term All-Cause Mortality in Patients with Non-ST-Elevation Acute Coronary Syndrome Managed with Routine Invasive Versus Selective Invasive Strategies","volume":"119","author":"Elgendy","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamacardio.2020.1251","article-title":"Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis","volume":"5","author":"Bainey","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJMoa1907775","article-title":"Complete Revascularization with Multivessel PCI for Myocardial Infarction","volume":"381","author":"Mehta","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e015263","DOI":"10.1161\/JAHA.119.015263","article-title":"Complete Revascularization by Percutaneous Coronary Intervention for Patients with ST-Segment-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: An Updated Meta-Analysis of Randomized Trials","volume":"9","author":"Ahmad","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jjcc.2022.07.003","article-title":"Treatment strategies of acute myocardial infarction: Updates on revascularization, pharmacological therapy, and beyond","volume":"81","author":"Saito","year":"2023","journal-title":"J. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2003.12.059","article-title":"A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: The Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial","volume":"44","author":"Sutton","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/2047487320913379","article-title":"Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology","volume":"28","author":"Ambrosetti","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/2047487320924912","article-title":"Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC)","volume":"28","author":"Abreu","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"113","author":"Navarese","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ehjcvp\/pvy034","article-title":"Effect of oral \u03b2-blocker treatment on mortality in contemporary post-myocardial infarction patients: A systematic review and meta-analysis","volume":"5","author":"Sandven","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-Blockers and Mortality After Acute Myocardial Infarction in Patients without Heart Failure or Ventricular Dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: Nationwide cohort study","volume":"41","author":"Kim","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"ACE Inhibitor Myocardial Infarction Collaborative Group (1998). Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation, 97, 2202\u20132212.","DOI":"10.1161\/01.CIR.97.22.2202"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/heartjnl-2012-301632","article-title":"Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: Long-term follow-up of a cohort of patients commonly using PPI co-therapy","volume":"98","author":"Scheiman","year":"2012","journal-title":"Heart."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: Insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials","volume":"374","author":"Braunwald","year":"2009","journal-title":"Lancet"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.2021.18323","article-title":"Cardiogenic Shock After Acute Myocardial Infarction: A Review","volume":"326","author":"Samsky","year":"2021","journal-title":"JAMA"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/eurheartj\/ehz363","article-title":"Management of cardiogenic shock complicating myocardial infarction: An update 2019","volume":"40","author":"Thiele","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1161\/CIR.0000000000000959","article-title":"Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement from the American Heart Association","volume":"143","author":"Henry","year":"2021","journal-title":"Circulation"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.acvd.2019.12.005","article-title":"New insights into cardiogenic shock and coronary revascularization after acute myocardial infarction","volume":"113","author":"Gerbaud","year":"2020","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jchf.2017.09.015","article-title":"Post-Myocardial Infarction Heart Failure","volume":"6","author":"Bahit","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"83","DOI":"10.59249\/LSWK8578","article-title":"Arrhythmias After Acute Myocardial Infarction","volume":"96","author":"Frampton","year":"2023","journal-title":"Yale J. Biol. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1540-8191.2009.00896.x","article-title":"Surgical treatment of postinfarction left ventricular free wall rupture","volume":"24","author":"Haddadin","year":"2009","journal-title":"J. Card. Surg."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1111\/jocs.15701","article-title":"Meta-analysis of surgical treatment for postinfarction left ventricular free-wall rupture","volume":"36","author":"Matteucci","year":"2021","journal-title":"J. Card. Surg."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jcin.2019.04.039","article-title":"Temporal Trends and Outcomes of Mechanical Complications in Patients with Acute Myocardial Infarction","volume":"12","author":"Elbadawi","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_167","first-page":"554","article-title":"Coronary angioplasty reduces free wall rupture and improves mortality and morbidity of acute myocardial infarction","volume":"16","author":"Nishiyama","year":"2004","journal-title":"J. Invasive Cardiol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bjsports-2018-099093","article-title":"Dose-response associations of cardiorespiratory fitness with all-cause mortality and incidence and mortality of cancer and cardiovascular and respiratory diseases: The UK Biobank cohort study","volume":"53","author":"Steell","year":"2019","journal-title":"Br. J. Sports Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40520-016-0705-4","article-title":"DosePhysical activity and exercise as countermeasures to physical frailty and sarcopenia","volume":"29","author":"Marzetti","year":"2017","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Muscella, A., Stef\u00e0no, E., Lunetti, P., Capobianco, L., and Marsigliante, S. (2020). The Regulation of Fat Metabolism During Aerobic Exercise. Biomolecules., 10.","DOI":"10.3390\/biom10121699"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/cvr\/cvab173","article-title":"Dietary recommendations for prevention of atherosclerosis","volume":"118","author":"Riccardi","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Matei, D., Buculei, I., Luca, C., Corciova, C.P., Andritoi, D., Fuior, R., Iordan, D.A., and Onu, I. (2022). Impact of Non-Pharmacological Interventions on the Mechanisms of Atherosclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169097"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-010-1848-1","article-title":"Meta-analysis of the acute effects of nicotine and smoking on human performance","volume":"210","author":"Heishman","year":"2010","journal-title":"Psychopharmacology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"105700","DOI":"10.1016\/j.phrs.2021.105700","article-title":"Cytisine and cytisine derivatives. More than smoking cessation aids","volume":"170","author":"Gotti","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_175","first-page":"online","article-title":"Varenicline for Smoking Cessation","volume":"96","author":"Crawford","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2217\/fca-2020-0211","article-title":"Canakinumab for secondary prevention of coronary artery disease","volume":"17","author":"Capodanno","year":"2021","journal-title":"Future Cardiol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"176338","DOI":"10.1016\/j.ejphar.2024.176338","article-title":"Hegemony of inflammation in atherosclerosis and coronary artery disease","volume":"966","author":"Attiq","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_178","first-page":"760","article-title":"Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease","volume":"72","author":"Fuster","year":"2019","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10557-020-07106-6","article-title":"Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications","volume":"36","author":"Montarello","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/eurheartj\/ehab644","article-title":"Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism","volume":"43","author":"Haghikia","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","article-title":"Association of Interleukin 6 Inhibition with Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial","volume":"8","author":"Adamstein","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Chen, H., Hong, L., Wang, H., Li, B., Zhang, M., Li, J., Yang, L., and Liu, F. (2023). Inclisiran: A new generation of lipid-lowering siRNA therapeutic. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1260921"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Dec, A., Niemiec, A., Wojciechowska, E., Malig\u0142\u00f3wka, M., Bu\u0142dak, \u0141., Bo\u0142dys, A., and Okopie\u0144, B. (2023). Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076858"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"108507","DOI":"10.1016\/j.pharmthera.2023.108507","article-title":"Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events","volume":"250","author":"Raschi","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/ATVBAHA.116.308895","article-title":"Janus Kinase 3, a Novel Regulator for Smooth Muscle Proliferation and Vascular Remodeling","volume":"37","author":"Wang","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.yjmcc.2011.03.005","article-title":"Vascular smooth muscle Jak2 deletion prevents angiotensin II-mediated neointima formation following injury in mice","volume":"50","author":"Kirabo","year":"2011","journal-title":"J. Mol. Cell Cardiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7295\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:09:20Z","timestamp":1760108960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":186,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25137295"],"URL":"https:\/\/doi.org\/10.3390\/ijms25137295","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}